Neuraminidase reprograms lung tissue and potentiates lipopolysaccharide-induced acute lung injury in mice.
We previously reported that removal of sialyl residues primed PBMCs to respond to bacterial LPS stimulation in vitro. Therefore, we speculated that prior desialylation can sensitize the host to generate an enhanced inflammatory response upon exposure to a TLR ligand, such as LPS, in a murine model of acute lung injury. Intratracheal instillation of neuraminidase (NA) 30 min prior to intratracheal administration of LPS increased polymorphonuclear leukocytes (PMNs) in the bronchoalveolar lavage fluid and the wet-to-dry lung weight ratio, a measure of pulmonary edema, compared with mice that received LPS alone. Administration of NA alone resulted in desialylation of bronchiolar and alveolar surfaces and induction of TNF-α, IL-1β, and chemokines in lung homogenates and bronchoalveolar lavage fluid; however, PMN recruitment in mice treated with NA alone did not differ from that of PBS-administered controls. NA pretreatment alone induced apoptosis and markedly enhanced LPS-induced endothelial apoptosis. Administration of recombinant Bcl-2, an antiapoptotic molecule, abolished the effect of NA treatment on LPS-induced PMN recruitment and pulmonary edema formation. We conclude that NA pretreatment potentiates LPS-induced lung injury through enhanced PMN recruitment, pulmonary edema formation, and endothelial and myeloid cell apoptosis. A similar "reprogramming" of immune responses with desialylation may occur during respiratory infection with NA-expressing microbes and contribute to severe lung injury.
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201;
Chiguang
C
Feng
Lei
L
Zhang
Chinh
C
Nguyen
Stefanie N
SN
Vogel
Simeon E
SE
Goldblum
William C
WC
Blackwelder
Alan S
AS
Cross
D055371:Acute Lung Injury / Q000139:chemically induced / Q000276:immunology*; D000818:Animals; D017209:Apoptosis / Q000276:immunology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000378:metabolism; D008070:Lipopolysaccharides / Q000008:administration & dosage; D008168:Lung / Q000166:cytology / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D022423:Myeloid Cells / Q000378:metabolism; D019158:N-Acetylneuraminic Acid / Q000378:metabolism; D009439:Neuraminidase / Q000008:administration & dosage / Q000378:metabolism*; D009504:Neutrophils / Q000276:immunology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000008:administration & dosage / Q000378:metabolism; D011654:Pulmonary Edema / Q000276:immunology
D008070:Lipopolysaccharides; D019253:Proto-Oncogene Proteins c-bcl-2; D009439:Neuraminidase; D019158:N-Acetylneuraminic Acid